Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DICE DICE Therapeutics (DICE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About DICE Therapeutics Stock (NASDAQ:DICE) 30 days 90 days 365 days Advanced Chart Ad WealthPressI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Get DICE Therapeutics alerts:Sign Up Key Stats Today's Range$47.55▼$47.5550-Day Range$46.62▼$47.5552-Week Range$15.08▼$47.90VolumeN/AAverage Volume1.03 million shsMarket Capitalization$2.27 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More… I hate to say I told you so (Ad)Last month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Receive DICE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DICE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DICE Stock News HeadlinesC4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH ReadoutNovember 6, 2024 | seekingalpha.comEli Lilly and Company (NYSE:LLY) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…November 23, 2024 | WealthPress (Ad)Buy, Sell, Or Hold LLY Stock At $850?October 31, 2024 | forbes.comWe tried Factor’s prepared meal delivery service for over three years: Full reviewOctober 12, 2024 | msn.comEverything You Need To Know About Zelda: Echoes Of WisdomSeptember 26, 2024 | msn.comSteven Schumacher joins Stoke City list of doom as ruthless Jon Walters takes responsibilitySeptember 16, 2024 | msn.comEli Lilly and Company (LLY): Jim Cramer's Go-To Stock For SuccessAugust 31, 2024 | msn.comSee More Headlines DICE Stock Analysis - Frequently Asked Questions How were DICE Therapeutics' earnings last quarter? DICE Therapeutics, Inc. (NASDAQ:DICE) released its earnings results on Friday, November, 12th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $1.77. When did DICE Therapeutics IPO? DICE Therapeutics (DICE) raised $160 million in an initial public offering on Wednesday, September 15th 2021. The company issued 10,000,000 shares at $15.00-$17.00 per share. What other stocks do shareholders of DICE Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DICE Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Honeywell International (HON), HubSpot (HUBS), Walt Disney (DIS) and Bank of America (BAC). Company Calendar Last Earnings11/12/2021Today11/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DICE CUSIPN/A CIK1645569 Webwww.dicemolecules.com Phone650-566-1420FaxN/AEmployees71Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-83,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-22.01% Return on Assets-20.79% Debt Debt-to-Equity RatioN/A Current Ratio25.88 Quick Ratio32.44 Sales & Book Value Annual Sales$1.13 million Price / Sales2,008.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.86 per share Price / Book4.38Miscellaneous Outstanding Shares47,731,000Free Float45,392,000Market Cap$2.27 billion OptionableNot Optionable Beta1.03 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:DICE) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DICE Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DICE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DICE Stock Alerts